Combined, the results of CAFFAP and CAFPDGFRβ support the theory of functionally different and/or context-dependent CAF subclasses exerting divergent immune-modulatory effects in NSCLC, despite the assumption that both FAP-1 and PDGFRβ are considered specific markers for activated CAFs. The gene discussed is PTPN13; the disease is non-small cell lung carcinoma.